TY - JOUR
T1 - Controlled release of Rituximab from gold nanoparticles for phototherapy of malignant cells
AU - Bisker, Gili
AU - Yeheskely-Hayon, Daniella
AU - Minai, Limor
AU - Yelin, Dvir
N1 - Funding Information: The authors thank Prof. Doron Melamed for providing the Burkitt lymphoma cell line, Prof. Eldad J. Dann for valuable discussions, and Lior Golan for his technical assistance. This work was funded in part by the European Research Council starting grant ( 239986 ) and by the Lorry I. Lokey Interdisciplinary Center for Life Sciences and Engineering .
PY - 2012/9/10
Y1 - 2012/9/10
N2 - Releasing drug molecules at their targets with high spatial and temporal accuracy could aid numerous clinical applications which require low systemic damage and low side effects. Nano-carriers of drugs are an attractive solution for such task, allowing specific accumulation in tumors and gradual release of their payload. Here, we utilize gold nanospheres conjugated to Rituximab, an anti-CD20 monoclonal antibody-based drug, for carrying and releasing the drug upon irradiation of specifically tailored femtosecond laser pulses. The released anti-CD20 molecules retain their functionality and ability of triggering the complement-dependent cytotoxicity. This effect comes in addition to cell necrosis caused by the plasmonic nanometric shock waves emanating from the nanospheres and rupturing the plasma membranes. Main advantages of the presented technique include high spatial and temporal resolution, low toxicity and high repeatability and consistency due to the morphological stability of the nanospheres.
AB - Releasing drug molecules at their targets with high spatial and temporal accuracy could aid numerous clinical applications which require low systemic damage and low side effects. Nano-carriers of drugs are an attractive solution for such task, allowing specific accumulation in tumors and gradual release of their payload. Here, we utilize gold nanospheres conjugated to Rituximab, an anti-CD20 monoclonal antibody-based drug, for carrying and releasing the drug upon irradiation of specifically tailored femtosecond laser pulses. The released anti-CD20 molecules retain their functionality and ability of triggering the complement-dependent cytotoxicity. This effect comes in addition to cell necrosis caused by the plasmonic nanometric shock waves emanating from the nanospheres and rupturing the plasma membranes. Main advantages of the presented technique include high spatial and temporal resolution, low toxicity and high repeatability and consistency due to the morphological stability of the nanospheres.
KW - Complement dependent cytotoxicity
KW - Controlled drug release
KW - Femtosecond pulses
KW - Gold nanoparticles
KW - Plasmon resonance
KW - Rituximab
UR - http://www.scopus.com/inward/record.url?scp=84865340800&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.jconrel.2012.06.030
DO - https://doi.org/10.1016/j.jconrel.2012.06.030
M3 - مقالة
C2 - 22759981
SN - 0168-3659
VL - 162
SP - 303
EP - 309
JO - Journal of Controlled Release
JF - Journal of Controlled Release
IS - 2
ER -
